Dupilumab – March 2026

Injection 300 mg in 2 mL single dose pre-filled syringe, Injection 300 mg in 2 mL single dose pre-filled pen

  • Brand names:
    • Dupixent®
  • Pharmaceutical Company:
    • SANOFI-AVENTIS AUSTRALIA PTY LTD
  • Condition/Indication: Chronic obstructive pulmonary disease (COPD)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026